Share

October 17, 2017; 89 (16) Article

Smoking cessation and outcome after ischemic stroke or TIA

Katherine A. Epstein, Catherine M. Viscoli, J. David Spence, Lawrence H. Young, Silvio E. Inzucchi, Mark Gorman, Brett Gerstenhaber, Peter D. Guarino, Anand Dixit, Karen L. Furie, Walter N. Kernan, For the IRIS Trial Investigators
First published September 8, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004524
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
361

Share

Article Information

vol. 89 no. 16 1723-1729
DOI: 
https://doi.org/10.1212/WNL.0000000000004524
PubMed: 
28887378
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 27, 2017
  • Accepted in final form July 14, 2017
  • First Published September 8, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Katherine A. Epstein, MA,
    2. Catherine M. Viscoli, PhD,
    3. J. David Spence, MD,
    4. Lawrence H. Young, MD,
    5. Silvio E. Inzucchi, MD,
    6. Mark Gorman, MD,
    7. Brett Gerstenhaber, MD,
    8. Peter D. Guarino, PhD,
    9. Anand Dixit, MD,
    10. Karen L. Furie, MD,
    11. Walter N. Kernan, MD;
    12. For the IRIS Trial Investigators
  1. Katherine A. Epstein, MA,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Catherine M. Viscoli, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. J. David Spence, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I was Assistant Editor of Stroke from 2000 to 2010, and am a member of the editorial board of Stroke from 2010-2016; a member of the editoral board of Hypertension from 2002-2016 of Arteriosclerosis, Thrombosis & Vascular Biology since ∼ 1995. I am a member of the Editorial Board of the Canadian Journal of Cardiology since 2015, and of Stroke and Vascular Neurology since 2016.

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1)How to prevent your stroke. Vanderbilt University Press 2006 (2) Stroke Prevention, Treatment and Rehabilitation. McGraw-Hill Medical, New York, 2012

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I have an interest in www.vascularis.com

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. I have received grants from the Heart & Stroke Foundation of Canada (Ontario) and the Canadian Institutes for Health Research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Vascularis Inc. 2010-present

    Legal Proceedings:

    1. NONE

  4. Lawrence H. Young, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent pending related to MIF family peptides in the treatment of myocardial infarction.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support to Yale University from (1) Merck (2) Novartis, (3) Mifcor.

    Research Support, Government Entities:

    1. Research support from (1) the NHLBI R01HL120622, PI, 2015-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. (1) MIF family peptides in the treatment of myocardial infarction, Yale University

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Silvio E. Inzucchi, MD,
    6. Scientific Advisory Boards:

    1. Merck, Sanofi/Lexicon, Novo-Nordisk, Intarcia, Janssen, Poxel, vTv Therapeutics, Eisai, Alere

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Diabetes Channel, Practice Update

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Boehringer Ingelheim, AstraZeneca

    Research Support, Government Entities:

    1. NIH

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mark Gorman, MD,
    7. Scientific Advisory Boards:

    1. I am on several DMCs for commercial entities: Symetis SA (Data Monitoring Committee for several (all that they have done) transapical and transfemoral valve studies); LivaNova (Clinical Event Committee for PERSIST-AVR trial); Harpoon Medical (Data Monitoring Committee for all current device-related studies).

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Brett Gerstenhaber, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Boehringer Ingelheim, speaker's fee

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Boehringer Ingelheim

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Peter D. Guarino, PhD,
    9. Scientific Advisory Boards:

    1. (1) NIAMS DSMB (2) DoD / VA Steering Committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Journal of Cardiac Failure, Consulting Editor, 2001 - 2009.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Fred Hutchinson Cancer Research Center, SCHARP Director, 2015 to present (2) Friends Research Institute, Inc., Biostatistician, 2001 - 2016

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Fred Hutchinson Cancer Research Center (2) Friends Research Institute, Inc.

    Research Support, Government Entities:

    1. (1) Department of Veterans Affairs, Cooperative Studies Program, Biostatistician 2001 - 2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Anand Dixit, MD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Karen L. Furie, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. sTROKE, vICE eDITOR 20 2011-PRESENT jOURNAL OF nEUROLOGY, nEURO SURGERY, PSYCHIATRY, dEPUTY eDITOR 2012-PRESENT

    Patents:

    1. NONE

    Publishing Royalties:

    1. uPtOdATE 2008-PRESENT

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. ninds, 2015-PRESENT

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Walter N. Kernan, MD;
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Yale receives research funding from NINDS and drug from Takeda Pharmaceuticals to support IRIS trial and support storage of blood in IRIS.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. For the IRIS Trial Investigators
    1. From the Yale School of Medicine (K.A.E., C.M.V., L.H.Y., S.E.I., B.G., W.N.K.), New Haven, CT; University of Western Ontario (J.D.S.), London, Canada; Maine Medical Center (M.G.), Portland; Fred Hutchinson Cancer Research Center (P.D.G.), Seattle, WA; University of Newcastle Upon Tyne (A.D.), Newcastle, UK; and Alpert Medical School of Brown University (K.L.F.), Providence, RI.
    1. Correspondence to Dr. Kernan: walter.kernan{at}yale.edu
    View Full Text

    Article usage

    Article usage: September 2017 to January 2023

    AbstractFullPdfSource
    Sep 20171817161Highwire
    Oct 201724873371Highwire
    Nov 20177161533Highwire
    Dec 20172381117Highwire
    Jan 20182031619Highwire
    Feb 201817086Highwire
    Mar 2018190124Highwire
    Apr 201821185Highwire
    May 201817496Highwire
    Jun 2018119107Highwire
    Jul 2018112710Highwire
    Aug 20188355Highwire
    Sep 201810731Highwire
    Oct 20188955Highwire
    Nov 20189113Highwire
    Dec 201814211Highwire
    Jan 20199513Highwire
    Feb 201910002Highwire
    Mar 201921542Highwire
    Apr 201920533Highwire
    May 201921044Highwire
    Jun 201912200Highwire
    Jul 201922121Highwire
    Aug 201934543Highwire
    Sep 201937344Highwire
    Oct 201938573Highwire
    Nov 201925820Highwire
    Dec 201915740Highwire
    Jan 20208140Highwire
    Feb 20209631Highwire
    Mar 20207802Highwire
    Apr 202010233Highwire
    May 20208833Highwire
    Jun 20209110Highwire
    Jul 20206112Highwire
    Aug 20208311Highwire
    Sep 202015022Highwire
    Oct 202012612Highwire
    Nov 202016132Highwire
    Dec 202013522Highwire
    Jan 202112563Highwire
    Feb 202113934Highwire
    Mar 202118100Highwire
    Apr 202118241Highwire
    May 202113765Highwire
    Jun 202117042Highwire
    Jul 202116410Highwire
    Aug 202114741Highwire
    Sep 202118522Highwire
    Oct 202114853Highwire
    Nov 202122755Highwire
    Dec 202113756Highwire
    Jan 202213621Highwire
    Feb 202214132Highwire
    Mar 202236731Highwire
    Apr 202240612Highwire
    May 202243070Highwire
    Jun 202234532Highwire
    Jul 202240365Highwire
    Aug 202225022Highwire
    Sep 202213282Highwire
    Oct 202215632Highwire
    Nov 202218868Highwire
    Dec 20229900Highwire
    Jan 202311333Highwire

    Cited By...

    Letters: Rapid online correspondence

    Comment

    REQUIREMENTS

    If you are uploading a letter concerning an article:
    You must have updated your disclosures within six months: http://submit.neurology.org

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Related Articles

    Topics Discussed

    Alert Me